ALFA Finder| Revenue growth | FY26 grew 10% YoY; FY27 guided at low double-digits. |
|---|---|
| Margins | Core margins 25%; US branded drag of 100-150 bps. |
| Demand visibility | Strong in Specialty, Animal Health; US branded scaling up. |
| Management confidence | High; focusing on execution-led model and specialty platform scaling. |
Growth
FY26 revenue up 10%; PAT up 16% to ₹675 Cr. Q4 India growth 4%, US generic growth positive.
Outlook
FY27 guidance: low double-digit consolidated revenue growth. Targeted R&D spend ₹750-800 Cr; Capex ₹300-350 Cr.
Risks
US pricing pressure, supply chain volatility, and initial margin drag from US branded business (Pivya).
Earnings Call filed with BSE, NSE: APLLTD. Summary written with AI assistance from the document.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,030.15
- Market cap
- ₹20,249 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 24.0×Sector 43.7×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Alembic Pharmaceuticals Other Announcement
Alembic Pharmaceuticals Limited has updated its list of Key Managerial Personnel authorised to determine materiality and make stock exchange disclosures. This update follows a board meeting held on November 4, 2026.
Alembic Pharmaceuticals Partnership
Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.
- From
- DifGen Pharmaceuticals
- Execution
- Initial launches from FY28
Alembic Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).
Alembic Pharmaceuticals Results Update
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
- Value
- ₹2,603 Cr
Alembic Pharmaceuticals Q2 FY27 Results: Net Profit ₹335.2 Cr, Up 81.5% YoY
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,604 Cr (+36.3% YoY) and net profit of ₹335.2 Cr (+81.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹335.2 Cr · +81.5% YoY